Traditional clinical trials rely on a ‘one-size-fits-all approach’, requiring participants to visit physical clinical trial sites. This visit is regardless of their location, mobility, or personal circumstances. This has proven to be a significant hurdle:

• 30% of participants drop out due to the burden of frequent site visits
• 60% of potential volunteers cite distance from the site as a primary barrier to enrolment

While historical frameworks like the Nuremberg Code and Good Clinical Practice prioritized patient protection, they did not emphasize patient involvement. The shift toward true patient centricity gained traction in the 2010s, fueled by patient advocacy and regulatory initiatives such as the FDA’s Patient-Focused Drug Development (PFDD) program. This program was formally launched around 2012, which invited patients and advocacy organizations to contribute their perspectives on diseases and treatment burdens directly to the regulatory process. This paved the way to involve patients as partners, not just as subjects—asking not only whether a treatment is safe and effective, but if it fits real patient needs and lifestyles.

The story of patient centricity is, in essence, the story of clinical research finally making the patient—not the study site, sponsor, or regulator—the protagonist. Advances in digital health and decentralized clinical trial capabilities propelled this shift even further, enabling:

• Home visits and telemedicine in place of clinic visits
• Direct-to-patient drug delivery and ePROs
• Trial protocols based on patient preferences via surveys and advisory boards

The COVID-19 pandemic accelerated these trends, demonstrating the feasibility of remote research without compromising data integrity or safety.

Though the roots (patient rights, safety) go back decades, meaningful patient centricity began in the last 10 to 15 years as a response to both advocacy and regulatory change, and has accelerated rapidly since the COVID-19 pandemic validated remote participation as feasible and effective. Today, patient centricity is recognized as essential for ethical, inclusive, and successful clinical research. Still, ongoing effort is needed to ensure every trial truly centers on the patient journey, not just pays lip service to it.

The lesson? Clinical trials CAN revolve around patients—not sites.

The Shift to Patient-Centric Research

What does “patient-centric” really mean?

• It’s more than convenience.
• It’s clinical trials redesigned for your needs, respecting your lifestyle, empowering you at every step.

The positive effects of patient centricity in clinical trials include:

• Enhanced accessibility for diverse populations in remote or rural areas
• Reduced participant burden through flexible scheduling and remote mode
• Enhanced informed consent processes to educate and empower participants
• Incorporation of patient feedback throughout trial design and conduct
• Respect for patient time and personal circumstances

Traditional trials often exclude people who need the innovations most from research. DCTs change that story.

The Real-World Impact of Decentralized Trials

Participants in DCTs report:

• Higher satisfaction due to reduced travel
• Better adherence when barriers are minimized
• Improved retention throughout the study
• Greater representation across demographics

By lowering participation burdens, DCTs not only empower patients but also improve the reliability and inclusiveness of research outcomes.

The result? 

More reliable and meaningful data translates to faster, safer, and more representative medical breakthroughs.

How Decentralized Clinical Trials Enable Patient-Centric Research

DCTs use advanced technologies to bring research directly to patients, making participation easier for them.

It enables a patient-centric approach in the clinical trial landscape by:

Home Healthcare Providers (HHCP): Trained healthcare professionals visit patients at home to conduct trial activities such as sample collection, drug administration, and assessments. This not only reduces travel but also ensures that patients receive personalized care in a familiar environment, improving comfort and compliance.

Telemedicine: Virtual consultations enable patients to interact with investigators and research staff remotely, without the need to leave their homes. Telemedicine has proven especially valuable for routine follow-ups, safety monitoring, and addressing participant concerns, thereby increasing engagement and retention.

Direct-to-Patient (DTP) Services: Investigational medicinal products and supplies are delivered directly to the patient’s home. DTP services reduce logistical barriers, improve adherence, and enable more diverse participation, particularly for individuals with limited mobility or residing in remote areas.

Patient-Facing Platforms (PFP): Digital platforms and mobile apps empower patients to record outcomes, access study information, and communicate with the research team. These tools enhance engagement, provide real-time data collection, and foster a sense of ownership over the clinical trial journey.

Electronic Patient-Reported Outcomes (ePROs): Digital platforms allow patients to easily record symptoms, quality of life measures, and treatment responses. These tools often include reminders and user-friendly interfaces that improve compliance and data quality.

Spotlight: DCTs in Bioequivalence and Real-World Studies

Are you part of a bioequivalence study, where researchers compare medicines for safety and effectiveness? DCTs allow you to stay in your real-life routine, minimizing artificial changes. This leads to more realistic, naturalistic data, crucial for high-quality results. 

The Role of Clinical Research Organizations in Patient-Centric DCTs

Forward-thinking clinical research organizations (CROs) are investing heavily in DCT capabilities, recognizing that patient centricity is now essential for successful trial conduct. These organizations are:

• Developing user-friendly technology platforms
• Training staff in virtual engagement techniques
• Creating flexible protocols that accommodate diverse patient needs
• Establishing partnerships with home healthcare providers
• Implementing robust data security measures for remote data collection

Challenges and Opportunities Ahead

India’s rapid digitalization, expansion of telemedicine (like eSanjeevani), and rising smartphone use create fertile ground for DCTs. While DCTs offer tremendous potential, successful implementation requires addressing several key considerations:

• Regulatory compliance across different jurisdictions
• Data privacy and security in distributed environments
• Technology accessibility for all patient populations
• Training for both patients and healthcare providers
• Quality assurance in decentralized settings

The future of clinical research lies in hybrid models that combine the best aspects of traditional and decentralized approaches, tailored to specific study requirements and patient populations.

Conclusion: A New Era of Inclusive Clinical Research

We’re in an era where anyone—from bustling metros to the quietest village—can participate in clinical trials. DCTs aren’t just a technological shift; they’re a revolution in inclusion, equity, and scientific advancement. Every patient now has the opportunity to contribute, learn, and benefit from medical research.

What if trials no longer came with geographical or logistical limitations? What if every patient, regardless of their location, had a voice in advancing science? With DCTs, that future is already unfolding.

Engaging YOU in the Future of Research

Clinical research is evolving, and you have a front-row seat. Polls, Q&A sessions, and virtual community forums give participants a voice. Patient stories shape new protocols. Want to share your journey or ideas? DCT platforms foster a community—your feedback helps build better trials. To know more about our decentralized clinical trial services, contact us now.